Lantheus Holdings (LNTH) Capital Expenditures Growth (3y) (2017 - 2026)
Lantheus Holdings (LNTH) Capital Expenditures Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 75.58% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 28.56% |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | -27.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.44% |
| Dec 31, 2025 | 18.81% |
| Sep 30, 2025 | 39.35% |
| Jun 30, 2025 | -49.60% |
| Mar 31, 2025 | 22.44% |
| Dec 31, 2024 | -102.05% |
| Dec 31, 2023 | -64.06% |
| Sep 30, 2023 | 89.64% |
| Jun 30, 2023 | 71.74% |
| Mar 31, 2023 | 46.27% |
| Dec 31, 2022 | 50.31% |
| Sep 30, 2022 | -62.08% |
| Jun 30, 2022 | 8.14% |
| Mar 31, 2022 | -32.88% |
| Dec 31, 2021 | 18.12% |
| Dec 31, 2020 | 0.61% |
| Sep 30, 2020 | 4.35% |
| Jun 30, 2020 | -12.81% |
| Mar 31, 2020 | -18.03% |
| Dec 31, 2019 | -879.91% |